BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA through Gamida Cell Ltd.
| FBTTX Fund | USD 28.80 0.01 0.03% |
Slightly above 62% of Fidelity Advisor's investor base is looking to short. The analysis of overall sentiment of trading Fidelity Advisor Biotechnology mutual fund suggests that many investors are alarmed at this time. Fidelity Advisor's investing sentiment can be driven by a variety of factors including economic data, Fidelity Advisor's earnings reports, geopolitical events, and overall market trends.
Fidelity |
BioLineRx Ltd. , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. , the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide , BioLineRxs FDA-approved stem cell mobilization agent indicated in combination with filgrastim for collection and subs
Read at finance.yahoo.com
 |
Fidelity Advisor Fundamental Analysis
We analyze Fidelity Advisor's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fidelity Advisor using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fidelity Advisor based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Ten Year Return
Ten Year Return Comparative Analysis
Fidelity Advisor is currently under evaluation in ten year return among similar funds. Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
Fidelity Advisor Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fidelity Advisor mutual fund to make a market-neutral strategy. Peer analysis of Fidelity Advisor could also be used in its relative valuation, which is a method of valuing Fidelity Advisor by comparing valuation metrics with similar companies.
Peers
Fidelity Advisor Related Equities
| FATEX | Fidelity Advisor | 1.13 | ||||
| FAGNX | Fidelity Advisor | 0.67 | ||||
| FACTX | Fidelity Advisor | 0.15 | ||||
| FBTIX | Fidelity Advisor | 0.06 | ||||
| FBTAX | Fidelity Advisor | 0.03 |
Other Information on Investing in Fidelity Mutual Fund
Fidelity Advisor financial ratios help investors to determine whether Fidelity Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Fidelity with respect to the benefits of owning Fidelity Advisor security.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |